Bibliography
- Pietrobon D, Striessnig J. Neurobiology of migraine. Nat Rev Neurosci 2003;4(5):386-98
- Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders. 2nd edition. Cephalalgia 2004;24(Suppl 1):9-160
- Lipton RB, Bigal ME. Ten lessons on the epidemiology of migraine. Headache 2007;47(Suppl 1):S2-9
- Goadsby PJ, Lipton RB, Ferrari MD. Migraine – current understanding and treatment. N Engl J Med 2002;346(4):257-70
- Krymchantowski A, Bigal ME. Rizatriptan in migraine. Expert Rev Neurother 2005;5(5):597-603
- Pascual J. A review of rizatriptan, a quick and consistent 5-HT1B/1D agonist for the acute treatment of migraine. Expert Opin Pharmacother 2004;5(3):669-77
- Swan SK, Alcorn H Jr, Rodgers A, et al. Pharmacokinetic profile of rizatriptan 10-mg tablet and 10-mg orally disintegrating tablet administered with or without water in healthy subjects: an open-label, randomized, single-dose, 3-period crossover study. J Clin Pharmacol 2006;46(2):172-8
- Lainez MJ, Evers S, Kinge E, et al. Preference for rizatriptan 10-mg wafer vs. eletriptan 40-mg tablet for acute treatment of migraine. Cephalalgia 2006;26(3):246-56
- Bell CF, Foley KA, Barlas S, et al. Time to pain freedom and onset of pain relief with rizatriptan 10 mg and prescription usual-care oral medications in the acute treatment of migraine headaches: a multicenter, prospective, open-label, two-attack, crossover study. Clin Ther 2006;28(6):872-80
- Davies GM, Santanello N, Lipton R. Determinants of patient satisfaction with migraine therapy. Cephalalgia 2000;20(6):554-60
- Lipton RB, Hamelsky SW, Dayno JM. What do patients with migraine want from acute migraine treatment? Headache 2002;42(Suppl 1):3-9
- Ng-Mak DS, Hu XH, Chen Y, et al. Times to pain relief and pain freedom with rizatriptan 10 mg and other oral triptans. Int J Clin Pract 2007;61(7):1091-111
- Moschiano F, D'amico D, Allais G, et al. Early triptan intervention in migraine: an overview. Neurol Sci 2005;26:s108-10
- Cady RK, Sheftell F, Lipton RB, et al. Effect of early intervention with sumatriptan on migraine pain: retrospective analyses of data from three clinical trials. Clin Ther 2000;22(9):1035-48
- Burstein R, Collins B, Jakubowski M. Defeating migraine pain with triptans: a race against the development of cutaneous allodynia. Ann Neurol 2004;55(1):19-26
- Tfelt-Hansen P, Block G, Dahlof C, et al. Guidelines for Controlled Trials of Drugs in Migraine. 2nd edition. Cephalalgia 2000;20(9):765-86
- Mathew NT, Kailasam J, Meadors L. Early treatment of migraine with rizatriptan: a placebo-controlled study. Headache 2004;44(6):669-73
- Hu XH, Raskin NH, Cowan R, et al. on behalf of the United States Migraine Study Protocol (USMAP) Group. Treatment of migraine with rizatriptan: when to take the medication. Headache 2002;42(1):16-20
- Cady R, Martin V, Mauskop A, et al. Efficacy of rizatriptan 10 mg administered early in a migraine attack. Headache 2006;46(6):914-24
- Dowson AJ, Massiou H, Aurora SK. Managing migraine headaches experienced by patients who self-report with menstrually related migraine: a prospective, placebo-controlled study with oral sumatriptan. J Headache Pain 2005;6(2):81-7
- Granella F, Sances G, Allais G, et al. Characteristics of menstrual and nonmenstrual attacks in women with menstrually related migraine referred to headache centres. Cephalalgia 2004;24(9):707-16
- Macgregor EA, Hackshaw A. Prevalence of migraine on each day of the natural menstrual cycle. Neurology 2004;63(2):351-3
- Mannix LK, Files JA. The use of triptans in the management of menstrual migraine. CNS Drugs 2005;19(11):951-72
- Silberstein SD, Massiou H, Le Jeunne C, et al. Rizatriptan in the treatment of menstrual migraine. Obstet Gynecol 2000;96(2):237-42
- Silberstein SD, Massiou H, McCarroll KA, Lines CR. Further evaluation of rizatriptan in menstrual migraine: retrospective analysis of long-term data. Headache 2002;42(9):917-23
- Mannix LK, Loder E, Nett R, et al. Rizatriptan for the acute treatment of ICHD-II proposed menstrual migraine: two prospective, randomized, placebo-controlled, double-blind studies. Cephalalgia 2007;27(5):414-21
- Nett R, Mannix L, Mueller L, et al. Efficacy of rizatriptan for ICHD-II pure menstrual migraine and menstrually related migraine. Headache 2007;47(5):784
- Adelman JU, Lipton RB, Ferrari MD, et al. Comparison of rizatriptan and other triptans on stringent measures of efficacy. Neurology 2001;57(8):1377-83
- Christie S, Gobel H, Mateos V, et al. Crossover comparison of efficacy and preference for rizatriptan 10 mg versus ergotamine/caffeine in migraine. Eur Neurol 2003;49(1):20-9
- Misra UK, Kalita J, Yadav RK. Rizatriptan vs. ibuprofen in migraine: a randomised placebo-controlled trial. J Headache Pain 2007;8(3):175-9
- Peroutka SJ. Beyond monotherapy: rational polytherapy in migraine. Headache 1998;38(1):18-22
- Krymchantowski A, Filho P-MF, Bigal ME. Rizatriptan vs. rizatriptan plus trimebutine for the acute treatment of migraine: a double-blind, randomized, cross-over, placebo-controlled study. Cephalalgia 2006;26:871-4
- Krymchantowski A. Combining therapies for the treatment of migraine: is there a role? Expert Rev Neurother 2005;5(2):145-7
- Krymchantowski AV, Barbosa JS. Rizatriptan combined with rofecoxib vs. rizatriptan for the acute treatment of migraine: an open label pilot study. Cephalalgia 2002;22(4):309-12
- Krymchantowski A V, Bigal ME. Rizatriptan versus rizatriptan plus rofecoxib versus rizatriptan plus tolfenamic acid in the acute treatment of migraine. BMC Neurol 2004;4(10):1-6
- Freitag FG, Diamond M, Diamond S, et al. Efficacy and tolerability of coadministration of rizatriptan and acetaminophen vs rizatriptan or acetaminophen alone for acute migraine treatment. Headache 2008; Feb 6 [Epub ahead of print]
- Aurora S, Shashidhar H, Barrodale P, et al. Gastric stasis in migraine: more than just a paroxysmal abnormality during a migraine attack. Headache 2006;46:57-63
- Aurora S, Shashidhar H, Barrodale P, et al. Gastric stasis occurs in spontaneous, visually induced, and interictal migraine. Headache 2007;47(10):1443-6
- Winner P. Triptans for migraine management in adolescents. Headache 2002;42(7):675-9
- Lewis D, Ashwal S, Hershey A, et al. Practice parameter: pharmacological treatment of migraine headache in children and adolescents: Report of the American Academy of Neurology Quality Standards Subcommittee and the Practice Committee of the Child Neurology Society. Neurology 2004;63(12):2215-24
- Hamalainen ML, Hoppu K, Valkeila E, Santavuori P. Ibuprofen or acetaminophen for the acute treatment of migraine in children: a double-blind, randomized, placebo-controlled, crossover study. Neurology 1997;48(1):103-7
- Visser WH, Winner P, Strohmaier K, et al. Rizatriptan 5 mg for the acute treatment of migraine in adolescents: results from a double-blind, single-attack study and two open-label, multiple-attack studies. Headache 2004;44(9):891-9
- Winner P, Lewis D, Visser WH, et al. Rizatriptan 5 mg for the acute treatment of migraine in adolescents: a randomized, double-blind, placebo-controlled study. Headache 2002;42(1):49-55
- Ahonen K, Hamalainen ML, Eerola M, Hoppu K. A randomized trial of rizatriptan in migraine attacks in children. Neurology 2006;67(7):1135-40
- Okuma H, Kitagawa Y, Takagi S. Clinical efficacy of rizatriptan for patients with migraine: efficacy of drug therapy for migraine accompanied by tension headache-like symptoms, focusing on neck stiffness. J Headache Pain 2005;6(6):455-8
- Kaniecki R, Ruoff GE, Smith T, et al. Prevalence of migraine and response to sumatriptan in patients self-reporting tension/stress headache. Curr Med Res Opin 2006;22(8):1535-44
- Marcus DA, Furman JM. Prevention of motion sickness with rizatriptan: a double-blind, placebo-controlled pilot study. Med Sci Monit 2006;12(1):I1-7
- Bayazit Y, Yilmaz M, Mumbuc S, Kanlikama M. Assessment of migraine-related cochleovestibular symptoms. Rev Laryngol Otol Rhinol (Bord) 2001;122(2):85-8
- Kayan A, Hood JD. Neuro-otological manifestations of migraine. Brain 1984;107(Pt 4):1123-42
- Neuhauser H, Radtke A, Von Brevern M, Lempert T. Zolmitriptan for treatment of migrainous vertigo: a pilot randomized placebo-controlled trial. Neurology 2003;60(5):882-3
- Yates BJ, Miller AD, Lucot JB. Physiological basis and pharmacology of motion sickness: an update. Brain Res Bull 1998;47:395-406
- US Food and Drug Administration. Potentially Life-Threatening Serotonin Syndrome with Combined Use of SSRIs or SNRIs and Triptan Medications. 2006. Available from: http://www.fda.gov/cder/drug/InfoSheets/HCP/triptansHCP.htm [Last accessed 19 March 2008]
- Evans RW. The FDA alert on serotonin syndrome with combined use of SSRIs or SNRIs and triptans: an analysis of the 29 case reports. MedGenMed [online] 2007;9(3):48. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2100123
- Tepper S, Allen C, Sanders D, et al. Coprescription of triptans with potentially interacting medications: a cohort study involving 240268 patients. Headache 2003;43(1):44-8
- Fiore M, Shields KE, Santanello N, Goldberg MR. Exposure to rizatriptan during pregnancy: post-marketing experience up to 30 June 2004. Cephalalgia 2005;25(9):685-8
- Olesen J, Diener HC, Husstedt IW, et al. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med 2004;350(11):1104-10
- Ho TW, Mannix LK, Fan X, et al. Randomized controlled trial of an oral CGRP antagonist, MK-0974, in acute treatment of migraine. Neurology 2007; Oct 3 [Epub ahead of print]